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ABSTRACT
Objective To investigate the efﬁcacy and safety of
etanercept (ETN) in paediatric subjects with extended
oligoarticular juvenile idiopathic arthritis (eoJIA), enthesitis-
related arthritis (ERA), or psoriatic arthritis (PsA).
Methods CLIPPER is an ongoing, Phase 3b, open-label,
multicentre study; the 12-week (Part 1) data are reported
here. Subjects with eoJIA (2–17 years), ERA (12–17 years),
or PsA (12–17 years) received ETN 0.8 mg/kg once weekly
(maximum 50 mg). Primary endpoint was the percentage
of subjects achieving JIA American College of
Rheumatology (ACR) 30 criteria at week 12; secondary
outcomes included JIA ACR 50/70/90 and inactive disease.
Results 122/127 (96.1%) subjects completed the study
(mean age 11.7 years). JIA ACR 30 (95% CI) was achieved
by 88.6% (81.6% to 93.6%) of subjects overall; 89.7%
(78.8% to 96.1%) with eoJIA, 83.3% (67.2% to 93.6%)
with ERA and 93.1% (77.2% to 99.2%) with PsA. For
eoJIA, ERA, or PsA categories, the ORs of ETN vs the
historical placebo data were 26.2, 15.1 and 40.7,
respectively. Overall JIA ACR 50, 70, 90 and inactive disease
were achieved by 81.1, 61.5, 29.8 and 12.1%, respectively.
Treatment-emergent adverse events (AEs), infections, and
serious AEs, were reported in 45 (35.4%), 58 (45.7%), and
4 (3.1%), subjects, respectively. Serious AEs were one case
each of abdominal pain, bronchopneumonia, gastroenteritis
and pyelocystitis. One subject reported herpes zoster and
another varicella. No differences in safety were observed
across the JIA categories.
Conclusions ETN treatment for 12 weeks was effective
and well tolerated in paediatric subjects with eoJIA, ERA and
PsA, with no unexpected safety ﬁndings.
Juvenile idiopathic arthritis ( JIA) is the most
common childhood chronic rheumatic disease.1–3
The term JIA covers seven mutually exclusive cat-
egories according to the International League of
Associations for Rheumatology (ILAR) classiﬁcation
criteria.4–6
Past differences in nomenclature make comparisons
between clinical studies difﬁcult, and there is limited
evidence-based information for the management of
some JIA categories.7 8 Non-steroidal anti-
inﬂammatory drugs (NSAIDs), intra-articular corti-
costeroids, and disease-modifying antirheumatic
drugs (DMARDs; methotrexate (MTX) and sulfasala-
zine (SSZ)) are the ﬁrst-line treatments,4 9 10 followed
by biologics, such as tumour necrosis factor inhibitors
(TNFi) or abatacept in non-responders.11–14 The
TNFi agent, etanercept (ETN), has shown both short-
term and long-term efﬁcacy and safety in paediatric
subjects with polyarticular course JIA.15–19 However,
the efﬁcacy and safety of ETN in speciﬁc ILAR cat-
egories, such as extended oligoarticular JIA (eoJIA),
enthesitis-related arthritis (ERA) and psoriatic arthritis
(PsA) has not been studied thoroughly.20–26
The objective of Part I of the CLinical Study In
Paediatric Patients of Etanercept for Treatment of
ERA, PsA, and Extended Oligoarthritis (CLIPPER)
study was to evaluate the efﬁcacy and safety of ETN
0.8 mg/kg once weekly (max 50 mg/week) in these
three categories over the initial 12-week period.
PATIENTS AND METHODS
Study design
The CLIPPER study is Phase 3b, open-label, prospect-
ive, multicentre, interventional study divided into two
parts: Part I (reported herein) relates to the 12-week
primary analyses, while Part II is ongoing and relates
to long-term safety and efﬁcacy. Subjects with eoJIA
(2–17 years), ERA (12–17 years), or PsA (12–
17 years) were enrolled and received ETN 0.8 mg/kg
once weekly (maximum dose 50 mg/week). The
protocol was reviewed and approved by independent
ethics committees/institutional review board at 38
centres in 19 countries included in the Paediatric
Rheumatology International Trials Organisation
(PRINTO).27 All parents/subjects signed and dated an
informed consent, and the study was approved by the
Open Access
Scan to access more
free content
1114 Horneff G, et al. Ann Rheum Dis 2014;73:1114–1122. doi:10.1136/annrheumdis-2012-203046
Clinical and epidemiological research
group.bmj.com on January 30, 2015 - Published by http://ard.bmj.com/Downloaded from 
local ethics committee. This study was conducted in compliance
with the ethical principles originating in or derived from the
Declaration of Helsinki, and in compliance with all International
Conference on Harmonisation Good Clinical Practice Guidelines.
Inclusion and exclusion criteria
Key inclusion criteria: subjects classiﬁed as eoJIA, ERA, or PsA5;
≥2 active joints (swollen or limitation of motion (LOM) accom-
panied by either pain or tenderness); history of intolerance or
unsatisfactory response to at least a 3-month course of ≥1
DMARD or, only for ERA, unsatisfactory response to at least a
1-month course of ≥1 NSAID; only one DMARD (MTX, SSZ,
chloroquine or hydroxychloroquine), one oral corticosteroid
≤0.2 mg/kg/day or 10 mg/day (whichever was less), and one
NSAID were allowed with no dose changes throughout the study.
Key exclusion criteria: other rheumatic diseases; pustular, or
erythrodermic psoriasis; active or history of tuberculosis or evi-
dence of latent tuberculosis, active uveitis within 6 months of
baseline, any live (attenuated) vaccine within 2 months of base-
line, any medically important infection within 1 month of base-
line, or any prior receipt of biologics. The following JIA
medications were prohibited during speciﬁed washout periods
based on the half-life of the product: immunosuppressive drugs
(other than glucocorticosteroids or allowed medication) or leﬂu-
nomide within 6 months, investigational non-biologic drugs
within 3 months, non-biologic DMARDs (other than MTX,
SSZ, hydroxychloroquine, or chloroquine), combinations of
non-biologic DMARDs, ultraviolet A/B, or psoralen plus UVA
within 4 weeks.
Assessments
The primary endpoint was the percentage of subjects achieving
JIA American College of Rheumatology (ACR) 30 criteria28 at
week 12. Since this was a single-arm open-label study, the
primary results were compared with two historical placebo
groups from (1) a meta-analysis of JIA studies29 and (2)
a 12-week randomised, double-blind, placebo-controlled
juvenile-onset spondyloarthropathy study (ERA subjects only).30
In addition, we compared our results with a historical active
control group from a 12-week open-label period of an ETN
study of subjects with polyarticular juvenile rheumatoid arthritis
( JRA).17 Secondary endpoints included the percentage of sub-
jects achieving JIA ACR 30 at all time points other than week
12, JIA ACR 50, 70, 90, inactive disease status with physician
global assessment (PGA) of disease activity set to zero (minimal
value on the scale corresponding to no disease activity),31 and
the changes from baseline to week 12 for each of the JIA ACR
core components28: PGA of disease activity visual analogue
scale (VAS; 0–10 on a 21-circle VAS); parent’s global assessment
of the child’s overall well being VAS (0–10 on a 21-circle VAS);
number of active joints (0–73); number of joints with LOM
(0–69); CRP levels in mg/l; cross-culturally adapted Childhood
Health Assessment Questionnaire (CHAQ) score, completed by
parent.32–34 Additional endpoints included parent’s assessment
of the child’s pain (0–10 VAS) and duration of morning stiffness
in minutes, completed by parents. Subjects with ERA were
also assessed with the tender entheseal assessment (0–66);
overall back pain and nocturnal back pain (0–100 mm VAS),
completed by parents35; modiﬁed Schober’s test36 in centi-
metres (cm). Subjects with PsA were also assessed for the extent
of psoriasis with the psoriasis body surface area (BSA) and PGA
of psoriasis (0–5).
Safety
Compliance was measured at the site by using vial counts, diary
cards and information provided by the parent and/or subject;
subjects were considered compliant if they received ≥80% of
planned ETN doses. Adverse events (AEs), including infections,
injection site reactions (ISRs), serious AEs (SAEs), including
serious infections, laboratory analyses and vital signs measure-
ments were recorded throughout the study (MedDRAV.14.0 dic-
tionary). To assess immunogenicity, serum samples at baseline,
week 12, or upon early withdrawal, were analysed for the pres-
ence of ETN antibodies and neutralising antibodies.
Figure 1 Subject disposition. Adverse events include infections. All subjects who discontinued ETN continued to be monitored for safety. *One
PsA subject withdrew early but had assessment data for Week 12; therefore, analyses were performed on n = 29 subjects.
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Statistical methods
The sample size was determined by the 100 subjects anticipated
to be enrolled in the study. It was expected that the half-width of
the 95% CI would be no more than 10% for estimation of the
JIA ACR 30 response rate. All efﬁcacy analyses were based on the
modiﬁed intent-to-treat (mITT) population deﬁned as all subjects
who received ≥1 dose of ETN. For the overall population, and
for each of the JIA categories, the analysis was based on the
observed cases (OC) data. Descriptive summary statistics for
observed data were provided. Logistic regression analysis was used
to compare the JIA ACR 30 data with historical placebo data and
historical active control data: ORs and corresponding 95% CI
were computed for the overall population and for each of the JIA
categories. Safety analyses were based on the mITT population.
RESULTS
Subjects
A total of 127 subjects (eoJIA n=60, ERA n=38 and PsA
n=29) were enrolled (ﬁgure 1) with 122 (96.1%) completing
week 12. Mean age, weight, height and body mass index (BMI)
were lower in the eoJIA subgroup than the ERA and PsA sub-
groups as per inclusion criteria (table 1). ERA subjects were pre-
dominantly male (30, 78.9%). Of the 29 subjects with PsA, 21
had psoriatic lesions (19 plaque psoriasis and 2 guttate psoria-
sis). Concomitant DMARDs were received by 85.8% of subjects
overall, with MTX most commonly used. SSZ and glucocorti-
coids were more frequently used in ERA subjects. All 127 sub-
jects were ≥80% compliant with ETN and 115 (90.6%) were
100% compliant.
Table 1 Demographic and disease characteristics at baseline
eoJIA
n=60
ERA
n=38
PsA
n=29
Overall
n=127
Age at baseline, years 8.6 (4.6) 14.5 (1.6) 14.5 (2.0) 11.7 (4.5)
2–4 years n (%) 15 (25.0) – – 15 (11.8)
5–11 years n (%) 23 (38.3) – – 23 (18.1)
12–17 years n (%) 22 (36.7) 38 (100.0) 29 (100.0) 89 (70.1)
Female, n (%) 41 (68.3) 8 (21.1) 23 (79.3) 72 (56.7)
Weight, kg 34.8 (18.9) 54.4 (8.8) 60.0 (14.2) 46.4 (19.0)
BMI, kg/m2 17.9 (3.6) 19.5 (2.4) 22.7 (4.5) 19.5 (4.0)
Age at onset 6.1 (4.5) 12.5 (2.1) 12.6 (2.7) 9.5 (4.8)
Disease duration, months 31.6 (31.7) 23.0 (19.8) 21.8 (20.2) 26.8 (26.4)
HLA-B27 presence, n (%) 9 (15.0) 26 (68.4) 3 (10.3) 38 (29.9)
Disease characteristics
PGA of disease activity VAS 5.0 (1.8) 5.4 (1.9) 4.7 (1.4) 5.0 (1.8)
Parent global assessment of child’s overall well-being VAS 4.8 (2.4) 5.4 (2.3) 4.6 (2.2) 5.0 (2.3)
No. of active joints 7.6 (5.1) 5.2 (3.6) 7.0 (4.3) 6.7 (4.6)
No. of joints with LOM 6.3 (4.4) 4.8 (4.0) 5.6 (4.1) 5.7 (4.2)
No. of painful joints 5.5 (4.1) 6.7 (4.9) 7.8 (7.0) 6.4 (5.2)
No. of swollen joints 6.5 (4.8) 3.8 (2.8) 5.6 (3.7) 5.5 (4.2)
CRP, mg/l* 6.3 (10.6) 15.3 (21.5) 3.2 (4.7) 8.2 (14.7)
CHAQ score 0.9 (0.7) 0.7 (0.5) 0.7 (0.6) 0.8 (0.6)
Parent global assessment of child’s pain VAS 4.8 (2.6) 5.8 (2.5) 4.6 (2.3) 5.1 (2.5)
Morning stiffness, minutes 72.8 (97.2) 89.3 (128.9) 54.3 (54.2) 73.5 (100.6)
JIA category-specific characteristics
Tender entheseal score – 5.9 (9.4) – –
Overall back pain VAS, mm – 25.9 (28.0) – –
Nocturnal back pain VAS, mm – 16.4 (27.8) – –
Modified Schober’s test, cm – 15.0 (1.9) – –
Psoriasis BSA, % – – 10.4 (13.4) –
PGA of psoriasis – – 1.8 (1.4)
Concomitant therapy, no. of subjects (%)†
Any DMARD 54 (90.0) 32 (84.2) 23 (79.3) 109 (85.8)
Methotrexate 49 (81.7) 18 (47.4) 19 (65.5) 86 (67.7)
Sulfasalazine 3 (5.0) 12 (31.6) 4 (13.8) 19 (15.0)
Chloroquine 1 (1.7) 0 0 1 (0.8)
Hydroxychloroquine 1 (1.7) 2 (5.3) 0 3 (2.4)
Oral corticosteroid 7 (11.7) 8 (21.1) 1 (3.5) 16 (12.6)
Oral NSAID 32 (53.3) 26 (68.4) 16 (55.2) 74 (58.3)
All values are mean (SD), unless otherwise specified.
*Normal ranges for CRP values were as follows: 0–3 years, female <7.9 mg/l, male <11.2 mg/l; 4–10 years, female <10.0 mg/l, male <7.0 mg/l; 11–14 years, female <8.1 mg/l, male
<7.6 mg/l; 15–17 years, female <7.9 mg/l, male <7.9 mg/l; 18–120 years, female <5.0 mg/l, male <5.0 mg/l.
†Number of patients within concomitant therapy groups differ from baseline only for oral NSAIDs where two subjects in each treatment group added an oral NSAID post baseline.
BSA, body surface area; CHAQ, Childhood Health Assessment Questionnaire; CRP, C-Reactive Protein; DMARD, disease-modifying anti-rheumatic drug; eoJIA, extended oligoarticular
Juvenile idiopathic arthritis; ERA, enthesitis-related arthritis; LOM, limitation of motion; NSAID, Non-steroidal anti-inflammatory drug; PGA, physician global assessment; VAS, Visual
Analogue Scale.
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Efﬁcacy
At week 12, overall 88.6% (95% CI 81.6% to 93.6%) of sub-
jects achieved JIA ACR 30 (ﬁgure 2A). JIA ACR 30 (95% CI)
was achieved by 89.7% (78.8% to 96.1%) of subjects with
eoJIA, 83.3% (67.2% to 93.6%) with ERA and 93.1% (77.2%
to 99.2%) with PsA. In comparison of the JIA ACR 30 result
overall with historical data from a meta-analysis of JIA studies,29
the ORs (95% CI) showed a signiﬁcant advantage of ETN over
placebo (OR 23.5; 12.5 to 44.3; ﬁgure 2B). For eoJIA, ERA,
and PsA categories, the ORs (95% CI) of ETN versus the histor-
ical placebo data29 were 26.2 (10.6 to 64.2), 15.1 (6.0 to 38.2)
and 40.7 (9.4 to 176.9), respectively. Compared with data from
subjects from a jo-SpA study,30 in subjects with ERA, OR
showed ETN to be signiﬁcantly more effective than placebo
(OR 6.7, 95% CI 1.7 to 26.3). The JIA ACR 30 response rate
in this study was comparable with the historical active control
data17 overall (OR 2.0; 0.5 to 8.3) and for the three JIA cat-
egories, eoJIA (OR 2.0; 0.4 to 9.8), ERA (OR 1.5; 0.2 to 10.4)
and PsA (OR 2.3; 0.2 to 21.3) (ﬁgure 2C). At week 12 (ﬁgure
3A) overall, JIA ACR 50, 70 and 90 responses (95% CI) were
achieved by 81.1% (73.1% to 87.7%), 61.5% (52.2% to
70.1%) and 29.8% (21.8% to 38.7%) of subjects, respectively.
In subjects with eoJIA, the JIA ACR 50/70/90 response rates
were generally similar across the three age groups (ﬁgure 3B). In
total, inactive disease (95% CI) was achieved by 12.1% (6.9%
to 19.2%) by week 12; 11.9% (4.9% to 22.9%), 16.7% (6.4%
to 32.8%) and 6.9% (0.8% to 22.8%) in subjects with eoJIA,
ERA and PsA, respectively.
Figure 2 Juvenile idiopathic arthritis
(JIA) American College of
Rheumatology (ACR) response 30, 50,
70, 90 and inactive disease status.
(A) JIA ACR 30 response rates by JIA
category over 12 weeks. Data are
compared with historical placebo
data29, 30 and historical active
control.17 *JIA ACR 30 historical
placebo rate = 28.9% (95% CI 24.0 to
34.2; n = 323).29 †JIA ACR 30 historical
placebo rate = 42.8% (95% CI 16.9 to
68.8; n=14).30 ‡JIA ACR 30 historical
active-control response rate at Week
12 = 73.9% (95% CI 63.6 to 84.3;
n=69).17 (B) OR (95% CI) of JIA ACR
30 response rates at week 12 vs
historical placebo data. Observed
cases, mITT population. Log scale used
for horizontal axis. *JIA ACR 30
historical placebo rate = 28.9% (95%
CI 24.0, 34.2; n = 323).29 Six historical
studies treated individually in the
logistic regression model (adjusted).
**JIA ACR 30 historical placebo rate =
42.8% (95% CI 16.9, 68.8; n = 14).30
(C) OR (95% CI) of JIA ACR 30
response rates at week 12 vs historical
active control. Observed cases, mITT
population. Log scale used for
horizontal axis. Historical active control
data taken from;17 JIA ACR 30
response rate at Week 12 = 73.9%
(95% CI 63.6 to 84.3; n = 69).
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Overall, improvements greater than 50% from baseline at
week 12 were observed for each of the JIA ACR core compo-
nents (table 2).
In subjects with ERA, improvement greater than 50% from
baseline was observed for the tender entheseal score. For sub-
jects with PsA, 48.2% improvement in BSA of psoriasis and
39.6% improvement in PGA of psoriasis was observed.
Safety
Mean duration of ETN exposure was 12.6 (SD 1.6) weeks (29.2
subject-years). Mean weekly ETN dose was 35.0 (SD 13.1) mg.
Non-infectious treatment-emergent AEs (TEAEs; table 3)
occurred in 45 (35.4%) subjects leading to discontinuation in
two subjects: one for asthenia and pyrexia (considered severe
and unrelated to ETN) and the other for fatigue, dizziness and
wheezing (considered moderate and related to ETN); both
resolved without sequelae. Overall, the most commonly
reported non-infectious TEAEs were headache, abdominal pain,
diarrhoea, fatigue and pyrexia. No differences in the rates of
non-infectious TEAEs were observed among the three categor-
ies. For subjects with eoJIA, ﬁve (33.3%), 10 (43.5%) and six
(27.3%) subjects reported non-infectious TEAEs in the
2–4 years, 5–11 years and 12–17 years age groups, respectively.
No clinically meaningful differences in non-infectious TEAEs
were observed across these three age groups.
Treatment-emergent infections were reported in 58 (45.7%)
subjects mainly upper respiratory tract infection, pharyngitis
and rhinitis. Two (1.6%) subjects withdrew from ETN treatment
due to treatment-emergent serious infections: one case each of
bronchopneumonia and pyelocystitis. Both cases led to hospital-
isation and were considered mild and unrelated to ETN and
resolved without sequelae. No differences in the rates of
treatment-emergent infections were observed among the three
categories. Treatment-emergent infections by age group in the
eoJIA subjects were 11 (73.3%), 12 (52.2%) and 8 (36.4%) for
2–4 years, 5–11 years and 12–17 years, respectively. One mild
case of an uncomplicated scarlet fever occurred in a 4-year-old
male and resolved in 11 days with anti-infective agent
treatment.
For non-infectious SAEs, there was one case (0.8%) of
abdominal pain which led to hospitalisation, resolved without
sequelae, and considered moderate and unrelated to ETN.
Serious treatment-emergent infections considered medically
important were reported in three (2.4%) subjects: one case each
of gastroenteritis and the cases of bronchopneumonia and pye-
locystitis mentioned previously, all resolved within a week. Two
(1.6%) cases of infections considered preventable by vaccination
were reported in subjects not previously vaccinated: one case of
varicella and one case of herpes zoster occurring in two derma-
tomes. No cases of malignancy, autoimmune disorders, demye-
linating disorders, infections considered preventable by
vaccination in subjects previously vaccinated, or deaths were
reported.
Five (4.0%) subjects had Grade 3 laboratory test results: three
(2.4%) with decreased neutrophil values, one (0.8%) with
increased total bilirubin values and one (0.8%) with increased
alkaline phosphatase values. Overall, 10 subjects had increased
aminotransferase (AT) values, with eight subjects reporting peak
Figure 3 Juvenile idiopathic arthritis
( JIA) American College of Rheumatology
(ACR) 50, 70, 90 responses and inactive
disease at week 12. (A) JIA ACR 50, 70,
90 responses and inactive disease status
(secondary outcomes) according to JIA
category at week 12. (B) JIA ACR 30, 50,
70, 90 responses and inactive disease
according to age groups in eoJIA at
week 12. Observed cases, mITT
population. Error bars represent 95% CI.
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increase of >2× to ≤3× upper limit of normal (ULN) AT, and
two subjects reporting >3× ULN AT values. A total of seven
(5.5%) subjects tested positive for anti-ETN antibodies, ﬁve of
these had ERA and two had PsA. None of these subjects tested
positive for neutralising antibodies. The presence of ETN anti-
bodies did not have an apparent impact on efﬁcacy or safety.
Vital signs of potential clinical interest were observed in six
subjects. Of these, one had a decreased diastolic blood pressure
of 40 mm Hg. The other ﬁve cases were of elevated systolic
blood pressure ranging from 141 mm Hg to 150 mm Hg which
were Grade 2 in severity.
DISCUSSION
This open-label study provides evidence that ETN at 0.8 mg/kg
once weekly is both effective and well tolerated in paediatric
subjects with eoJIA, ERA, or PsA over 12 weeks of treatment.
Beyond the effectiveness of ETN that was reﬂected in the
arthritis-related variables measured in all three categories, there
were substantial improvements in the tender entheseal score,
back pain and nocturnal back pain in ERA patients, as well as
improvements in BSA and PGA of psoriasis in PsA patients.
Until now, information on the safety and efﬁcacy of ETN in
paediatric subjects has been obtained largely from polyarticular
course JIA. This functional class, deﬁned as having at least ﬁve
active joints, comprises about one-third of JIA, and includes
extended oligoarthritis, and polyarthritis rheumatoid factor
positive or negative or systemic arthritis without systemic sign/
symptoms at the time of drug initiation.4 Our study was specif-
ically designed with the aim to investigate the effect of ETN
treatment on three speciﬁc JIA categories: eoJIA, ERA and PsA.
Although a limited number of eoJIA patients were included in
the publication by Lovell et al12 using the previous classiﬁcation
criteria of JRA, further study of this patient population was
determined to be of medical interest by the sponsor and the
regulatory agency due to the paucity of ETN data in eoJIA
patients.
Considering the existing information on the efﬁcacy of ETN
in polyarticular course JIA, it was deemed unethical to have a
placebo arm in this paediatric study. Therefore, placebo data
based on a meta-analysis from previous JIA studies were used as
one of the prespeciﬁed comparators. The JIA ACR 30 response
rates overall and for each category were signiﬁcantly higher than
the placebo historical control.29 In addition, a comparison of
Table 2 Changes from baseline in effectiveness measures at week 12
Change from baseline at week 12, mean (95% CI) [%]
JIA ACR core components
eoJIA
n=58
ERA
n=36
PsA
n=29
Overall
n=123
PGA of disease activity −3.5 (−3.9 to −3.1)
[−73.2%]
−3.9 (−4.6 to −3.3)
[−70.9%]
−3.0 (−3.5 to −2.5)
[−65.0%]
−3.5 (−3.8 to −3.2)
[−70.6%]
Parent global assessment of child’s overall well being −2.8 (−3.5 to −2.2)
[−53.1%]
−2.8 (−3.7 to −1.9)
[−47.6%]
−2.4 (−3.1 to −1.6)
[−47.7%]
−2.7 (−3.1 to −2.3)
[−50.2%]
No. of active joints −5.5 (−6.7 to −4.2)
[−69.8%]
−4.3 (−5.4 to −3.1)
[−77.7%]
−5.2 (−6.8 to −3.6)
[−73.8%]
−5.1 (−5.8 to −4.3)
[−73.0%]
No. of joints with LOM −4.5 (−5.6 to −3.3)
[−64.1%]
−3.4 (−4.1 to −2.6)
[−67.4%]
−4.3 (−5.7 to −2.9)
[−71.7%]
−4.1 (−4.8 to −3.4)
[−66.9%]
CRP*, mg/l −2.8 (−4.9 to −0.7)
[−18.9%]
−13.2 (−20.5 to −5.8)
[−36.8%]
−1.3 (−2.8 to −0.20)
[−11.0%]
−5.4 (−7.8 to −2.9)
[−22.1%]
CHAQ −0.5 (−0.7 to −0.4)
[−52.2%]
−0.5 (−0.7 to −0.3)
[−57.8%]
−0.4 (−0.6 to −0.2)
[−51.3%]
−0.5 (−0.6 to −0.4)
[−53.6%]
Other assessments
Parent global assessment of child’s pain VAS −3.2 (−3.8 to −2.5)
[−58.9%]
−3.2 (−4.2 to −2.2)
[−44.9%]
−2.6 (−3.4 to −1.8)
[−46.6%]
−3.0 (−3.5 to −2.6)
[−51.9%]
Morning stiffness (min) −60.3 (−83.6 to −37.0)
[−61.5%]
−65.6 (−97.6 to −33.6)
[−64.1%]
−47.9 (−67.3 to −28.6)
[−77.2%]
−58.9 (−73.7 to −44.1)
[−66.0%]
JIA category-specific assessments
Tender entheseal score – −4.4 (−6.3 to −2.4)
[−57.8%]
– –
Back pain VAS – −12.5 (−21.3 to −3.7)
[−21.2%]
– –
Nocturnal back pain VAS – −8.9 (−16.7 to −1.2)
[−6.8%]
– –
Modified Schober’s test† – 0.35‡ (−0.02 to 0.72)
[9.7%]
– –
BSA, % – – −6.7 (−10.6 to −2.9)
[−48.2%]
–
PGA of psoriasis§ – – −1.0 (−1.4 to −0.6)
[−39.6%]
–
All values are the mean change from baseline (95% CI) (% change from baseline). mITT population (observed cases).
*For CRP: eoJIA n=58, ERA n=34, PsA n=28 and total n=120.
†ERA n=35.
‡change from baseline calculated after subtracting 10 from the baseline and week 12 scores.
§PsA n=28.
ACR, American College of Rheumatology; BSA, body surface area; CHAQ, Childhood Health Assessment Questionnaire; CRP, C-Reactive Protein; eoJIA, extended oligoarticular Juvenile
idiopathic arthritis; ERA, enthesitis-related arthritis; LOM, limitation of motion; mITT, modified intent-to-treat; PGA, physician global assessment; VAS, visual analogue scale.
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subjects with ERA with placebo-treated subjects from a jo-SpA
study also yielded a similar outcome even if we acknowledge
that the Mexican population enrolled by Burgos-Vargas et al
might represent a more severe group of patients.30 A further
comparison of JIA ACR 30 results from this study to the open-
label period from the ﬁrst ETN study in subjects with
polyarticular-course JRA showed similar proportions of subjects
responding at 12 weeks.17 The percentages of subjects achieving
the JIA ACR 50 and 70 endpoints were relatively higher in this
study versus the original ETN study (64% and 36%, respect-
ively) in which subjects were given ETN 0.4 mg/kg twice weekly
but no concomitant DMARDs. Similar to other studies with
TNFi agents, it is possible that the concomitant administration
of DMARDs (mainly MTX), and the open-label design of our
study may have resulted in more favourable outcomes.
Although this is the ﬁrst study to prospectively investigate the
effect of ETN speciﬁcally in eoJIA, ERA and PsA patients, previ-
ous studies have included such subjects within their patient
population.23–26 37 A prospective observational study of TNFi
from the Dutch Arthritis and Biologicals in Children Registry
observed similar proportions of subjects with ERA achieving
JIA ACR 30 as observed in our study.23 The majority of these
subjects (n=20/22) were treated with ETN and concomitant
DMARD. After 3 months, 86% of subjects achieved JIA ACR
30 and 73% achieved JIA ACR 70. One-third achieved inactive
disease status (using the 2004 inactive disease criteria)38 which
was slightly higher than those observed in our study. Similar
results for the attainment of inactive disease status were
obtained in the German Registry.39 By contrast, another retro-
spective study at an academic centre showed paediatric subjects
with ERA receiving TNFi treatment were less likely to achieve
inactive disease after 1 year than other JIA categories.20 In our
study, the rate of inactive disease was similar in the three cat-
egories. A long-term observational analysis of subjects with PsA
(n=17/18 on ETN) from the Dutch Registry found similar
results to those shown here for the joint symptoms37 with 83%
of subjects achieving JIA ACR 30 after 3 months. Interestingly,
the skin symptoms of subjects with PsA and psoriasis in the
Dutch Registry did not respond well to treatment in contrast
with the observed improvements shown in BSA and PGA of
psoriasis in our study.
The efﬁcacy of ETN in the eoJIA group in this study is also
comparable with that observed in subjects with eoJIA treated
with adalimumab, inﬂiximab, or abatacept.11–13
Table 3 Summary of safety findings
No. of subjects (%)
eoJIA (n=60) ERA (n=38) PsA (n=29) Overall (n=127)
Treatment-emergent AEs* 21 (35.0) 16 (42.1) 8 (27.6) 45 (35.4)
Treatment-emergent AEs leading to withdrawal* 0 2 (5.3) 0 2 (1.6)
Treatment-emergent non-infectious AEs in ≥5% subjects
Headache 2 (3.3) 2 (5.3) 3 (10.3) 7 (5.5)
Abdominal pain 0 4 (10.5) 0 4 (3.1)
Diarrhoea 1 (1.7) 3 (7.9) 0 4 (3.1)
Fatigue 0 4 (10.5) 0 4 (3.1)
Pyrexia 3 (5.0) 1 (2.6) 0 4 (3.1)
Aspartate aminotransferase increased 3 (5.0) 0 0 3 (2.4)
Myalgia 0 3 (7.9) 0 3 (2.4)
Decreased appetite 0 2 (5.3) 0 2 (1.6)
Back pain 0 0 2 (6.9) 2 (1.6)
Epistaxis 0 2 (5.3) 0 2 (1.6)
Respiratory disorder 0 0 2 (6.9) 2 (1.6)
Allergic rhinitis 0 2 (5.3) 0 2 (1.6)
Wheezing 0 2 (5.3) 0 2 (1.6)
Treatment-emergent ISRs 4 (6.67) 4 (10.53) 2 (6.90) 10 (7.87)
Treatment-emergent infections 31 (51.7) 15 (39.5) 12 (41.4) 58 (45.7)
Treatment-emergent infections leading to withdrawal 1 (1.7) 0 1 (3.4) 2 (1.6)
Treatment-emergent infections ≥5% subjects
Upper respiratory tract infection 9 (15.0) 4 (10.5) 5 (17.2) 18 (14.2)
Pharyngitis 9 (15.0) 4 (10.5) 2 (6.9) 15 (11.8)
Rhinitis 4 (6.7) 2 (5.3) 2 (6.9) 8 (6.3)
Gastroenteritis 3 (5.0) 1 (2.6) 1 (3.4) 5 (3.9)
Bronchitis 1 (1.7) 3 (7.9) 0 4 (3.1)
Sinusitis 3 (5.0) 0 0 3 (2.4)
Treatment-emergent SAEs* 0 1 (2.6) 0 1 (0.8)
Serious treatment-emergent infections 2 (3.3) 0 1 (3.4) 3 (2.4)
Infections considered preventable by vaccination in subjects not previously vaccinated 1 (1.7) 1 (2.6) 0 2 (1.6)
Medically important infections 2 (3.3) 0 1 (3.4) 3 (2.4)
Opportunistic infections 0 1 (2.6) 0 1 (0.8)
No incidences of serious treatment-emergent injection site reactions (ISRs), infections considered preventable by vaccination in subjects previously vaccinated, autoimmune disorders,
demyelinating disorders, malignancies were reported and therefore not included in this table.
*Excluding infections and ISRs.
AEs, adverse events; ERA, enthesitis-related arthritis; eoJIA, extended oligoarticular juvenile idiopathic arthritis; PsA, psoriatic arthritis; SAEs, serious AEs.
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ETN was well tolerated in this paediatric population for up
to 12 weeks. Three serious infections were reported: one case each
of gastroenteritis, bronchopneumonia and pyelocystitis. One case
of herpes zoster was also reported. No cases of malignancy, auto-
immune disorders, demyelinating disorders, infections considered
preventable by vaccination in subjects previously vaccinated, or
deaths were reported. However, the number of patient-years
accrued with ETN in this study is not sufﬁcient to draw any ﬁrm
safety conclusions, while Part II of the study, which aimed to evalu-
ate long-term safety, is still ongoing. The immunogenicity proﬁle of
ETN was favourable and consistent with studies in other paediatric
and adult populations.19
The study was limited methodologically by the open-label
design and use of historical data as the comparator instead of a
placebo-control group and the lack of imaging especially for the
ERA group. Additionally, subjects used different and varying con-
comitant therapies (DMARDs, glucocorticosteroids and NSAIDs)
that may have had an effect on the efﬁcacy responses. Another
limitation was the lower age limit for inclusion in the PsA and ERA
group which was set to 12 years; future studies should look at efﬁ-
cacy and safety proﬁles in lower age groups in PsA and ERA.
In conclusion, ETN 0.8 mg/kg once weekly treatment for
12 weeks was effective and well tolerated in children with
eoJIA, ERA and PsA. ETN was not associated with unexpected
safety ﬁndings reported in this paediatric population. The
results of Part 2 of the 96 weeks of the CLIPPER study will
provide further insight regarding the effects of ETN in these
speciﬁc JIA categories.
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